Grant: Master's Award: Canada Graduate Scholarships
University of Toronto
$17,500.00
Evaluating quality of gout treatment using a population health approach
FY 2021-22
Summary
Gout is a common form of arthritis that affects a large proportion of Canadians, leading to significant pain and disability. A major contributor to the development of gout is the presence of increased urate levels in the blood, which is associated with the formation of urate crystals in joints. The main cornerstone in gout treatment therefore involves the prevention of acute gout flares using medications that reduce serum urate to a pre-specified target level which has been shown to prevent the formation of gout crystals, as endorsed by the major rheumatology guidelines. Despite therapies available to lower urate levels, a large subset of patients still experience acute gout flares. One of the main contributors for this is due to poor treatment uptake and suboptimal urate monitoring. However, the scope of the care gap for gout has not been studied extensively in Canada.Therefore, this research project will specifically assess the achievement of treatment benchmarks in gout, using Ontario-wide health administrative data. This will allow us to determine the magnitude of gout treatment care gaps, using outcomes that have been endorsed by the American College of Rheumatology. Specifically, we will study the proportion of patients and factors associated with optimal monitoring of serum urate levels. Subsequently, we will assess the proportion of patients who achieve target urate levels 1 year after starting gout medications in addition to associated factors. This is the first Canadian study to evaluate the quality of gout care, using provincial-wide data. Given how common gout is within Canada, this research project will hopefully identify care gaps and mobilize quality improvement in gout treatment, potentially benefiting the 4% of all Canadians who suffer from gout.
Department
Program
Master's Award: Canada Graduate Scholarships
Recipient
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
466633
Name
Kwok Timothy
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Evaluating quality of gout treatment using a population health approach
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Adminstrative Data; Arthritis; Clinical Practice Guidelines; Gout; Health Services Research; Quality Of Care; Rheumatology
Abstract
Gout is a common form of arthritis that affects a large proportion of Canadians, leading to significant pain and disability. A major contributor to the development of gout is the presence of increased urate levels in the blood, which is associated with the formation of urate crystals in joints. The main cornerstone in gout treatment therefore involves the prevention of acute gout flares using medications that reduce serum urate to a pre-specified target level which has been shown to prevent the formation of gout crystals, as endorsed by the major rheumatology guidelines. Despite therapies available to lower urate levels, a large subset of patients still experience acute gout flares. One of the main contributors for this is due to poor treatment uptake and suboptimal urate monitoring. However, the scope of the care gap for gout has not been studied extensively in Canada.Therefore, this research project will specifically assess the achievement of treatment benchmarks in gout, using Ontario-wide health administrative data. This will allow us to determine the magnitude of gout treatment care gaps, using outcomes that have been endorsed by the American College of Rheumatology. Specifically, we will study the proportion of patients and factors associated with optimal monitoring of serum urate levels. Subsequently, we will assess the proportion of patients who achieve target urate levels 1 year after starting gout medications in addition to associated factors. This is the first Canadian study to evaluate the quality of gout care, using provincial-wide data. Given how common gout is within Canada, this research project will hopefully identify care gaps and mobilize quality improvement in gout treatment, potentially benefiting the 4% of all Canadians who suffer from gout.
Competitiondate
202112
Approvedterm2
1 yr 0 mth
Pinamesdelim
Kwok, Timothy
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~